Pharming wins FDA Priority Review for lower-dose Joenja in children with APDS
AI Summary- Pharming announced FDA acceptance of its lower-dose Joenja application for children with APDS.
- Joenja’s supplemental application received Priority Review from the U.S. FDA.
- APDS is the condition targeted by the pediatric treatment submission.